SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
130.20    2.40 (1.88%)
Bid:
130.00
Ask:
130.40
Spread: 0.40 (0.308%)
Market Cap: £268.15m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

Trading Update

3 Jun 2020 07:00

RNS Number : 7409O
Forterra plc
03 June 2020
 

Forterra plc

 

3 June 2020 

 

 Trading Update

 

Forterra plc, a leading UK producer of manufactured masonry products, provides this update and further detail on the measures it is taking to mitigate the impact of Covid-19.

 

Trading and operational update

 

Since our announcement of 28 April 2020, we have been encouraged by a gradual increase in despatches as our customers reopened their operations. Daily despatches of our brick & block products have now recovered to approximately 50% of corresponding 2019 levels. Group revenue declined by 39% for the five months to 31 May 2020 compared with the corresponding period in 2019, with a year-on-year decline of 86% in April and 62% in May.

 

We are currently manufacturing at twelve of our eighteen facilities and are preparing to further increase production as demand requires. We anticipate recommencing production at most of our remaining facilities by the end of July and retain full flexibility to reopen facilities sooner should demand increase at a faster rate than expected.

 

Restructuring

 

Economic and industry forecasts indicate a prolonged impact from Covid-19 on the UK economy and more specifically the construction sector. Although the Construction Products Association's most recent forecast anticipates the residential construction market will recover during 2021, output in 2021 is forecast to be approximately 20% lower than in 2019.

 

Accordingly, we are taking steps to restructure the Group's operations in line with the anticipated decline in medium-term demand. In the coming weeks we will consult with employees on our plans, which include proposed changes to shift patterns and adjustments to the size and structure of support functions. Additionally, these proposals include consolidating the manufacture of all precast concrete flooring products at our Hoveringham facility in Nottinghamshire. This proposal will necessitate the mothballing of our hollowcore flooring manufacturing facility at Swadlincote in Derbyshire once the current order book is completed. These proposals will not affect our ability to service key customers or our specialist precast concrete facility at Swadlincote. These actions, if implemented, will regrettably lead to the loss of approximately 225 jobs, primarily from our concrete products facilities.

 

Balance sheet and liquidity

The Group entered the Covid-19 crisis with net debt (pre IFRS 16) of £43.2m at 31 December 2019. 

The Group has access to a £150m revolving credit facility which runs to July 2022, which is presently fully drawn. At 31 May 2020 the Group had cash reserves of £79m as well as access to an undrawn overdraft facility of £10m.

In addition, Forterra plc has been confirmed as eligible for the joint HM Treasury and Bank of England Covid Corporate Financing Facility (CCFF) with an issuer limit of £175 million and is now able to access the liquidity available under this facility. The Board does not have any present intention to draw upon this facility, which provides the Group with additional headroom if required.

Summary

Despite the economic circumstances created by Covid-19, the Board remains confident that the Group is well positioned to take advantage of the attractive long-term market fundamentals in order to continue delivering sustainable shareholder value. 

Enquiries:

Forterra plc:

+44 (0) 1604 707 600

Stephen Harrison (CEO) / Ben Guyatt (CFO)

FTI Consulting:

+44 (0) 20 3727 1340

Richard Mountain / Nick Hasell

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) prior to its release as part of this announcement.

Further information relating to the Company and its group can be found at www.forterraplc.co.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBRGDLGBGDGGD
Date   Source Headline
10th Mar 20227:00 amRNSFinal Results
10th Mar 20227:00 amRNSTransaction in Own Shares
9th Mar 20227:00 amRNSTransaction in Own Shares
8th Mar 20227:00 amRNSTransaction in Own Shares
7th Mar 20227:00 amRNSTransaction in Own Shares
4th Mar 20227:00 amRNSTransaction in Own Shares
3rd Mar 20227:00 amRNSTransaction in Own Shares
2nd Mar 20224:32 pmRNSEmployee Benefit Trust Share Purchase
1st Mar 20227:00 amRNSTransaction in Own Shares
28th Feb 20225:00 pmRNSTotal Voting Rights
28th Feb 20227:00 amRNSTransaction in Own Shares
25th Feb 20227:00 amRNSTransaction in Own Shares
24th Feb 20227:00 amRNSTransaction in Own Shares
23rd Feb 20227:00 amRNSTransaction in Own Shares
22nd Feb 20227:00 amRNSTransaction in Own Shares
21st Feb 20227:00 amRNSTransaction in Own Shares
18th Feb 20227:00 amRNSTransaction in Own Shares
17th Feb 20227:00 amRNSTransaction in Own Shares
16th Feb 20228:26 amRNSHolding(s) in Company
16th Feb 20227:00 amRNSTransaction in Own Shares
15th Feb 20227:00 amRNSTransaction in Own Shares
14th Feb 20227:00 amRNSTransaction in Own Shares
11th Feb 20227:00 amRNSTransaction in Own Shares
10th Feb 20227:00 amRNSTransaction in Own Shares
9th Feb 20227:00 amRNSTransaction in Own Shares
8th Feb 20227:30 amRNSTransaction in Own Shares
8th Feb 20227:00 amRNSShare buyback programme
7th Feb 20227:00 amRNSTransaction in Own Shares
4th Feb 20227:00 amRNSTransaction in Own Shares
3rd Feb 20226:05 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 20227:00 amRNSTransaction in Own Shares
2nd Feb 20227:00 amRNSTransaction in Own Shares
1st Feb 20227:30 amRNSTransaction in Own Shares
31st Jan 20225:15 pmRNSTotal Voting Rights
31st Jan 20227:30 amRNSTransaction in Own Shares
28th Jan 20227:00 amRNSTransaction in Own Shares
26th Jan 20227:36 amRNSProgressive publishes new research
26th Jan 20227:00 amRNSPre-close trading update
6th Jan 20224:02 pmRNSEmployee Benefit Trust Share Purchase
3rd Dec 20215:31 pmRNSEmployee Benefit Trust Share Purchase
25th Nov 20218:01 amRNSProgressive publishes new research
25th Nov 20217:00 amRNSTrading Update
2nd Nov 20215:12 pmRNSEmployee Benefit Trust Share Purchase
1st Nov 20211:51 pmRNSDirector Declaration
13th Oct 20217:06 amRNSHolding(s) in Company
7th Oct 20215:12 pmRNSDirector/PDMR Shareholding
6th Oct 20217:51 amRNSHolding(s) in Company
5th Oct 20215:49 pmRNSEmployee Benefit Trust Share Purchase
28th Sep 20219:28 amRNSEmployee Benefit Trust Share Purchase
23rd Sep 20218:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.